B-LYMPHOPLASMACYTIC LYMPHOMA WITH WALDENSTRÖM’S MACROGLOBULINEMIA VARIANT

Authors:

Abstract:

A hematological malignant disease of human lymphoid tissue in the form of a rare Waldenström disease with a long asymptomatic course and short-term clinical course usually ends fatally for an elderly patient. Clinical verification of the disease is based on a monoclonal IgM diagnosis and bone marrow biopsy results. The purpose of the study was to deepen knowledge of the clinical course and pathomorphological diagnosis of lymphoid organ tumors of B-cell origin, specifically Waldenström macroglobulinemia, a variant of non-Hodgkin lymphoma. The research methods were a review of the professional scientific literature on the pathology of B-cell lymphomas and a retrospective clinical and anatomical analysis of a fatal case of Waldenström's disease in an elderly patient with a short clinical course and concomitant diseases of a compensated nature in the form of general vascular atherosclerosis and hypertension. As a result of the literature analysis, data were obtained on the molecular basis of the mechanism of formation of tumors of the immune system of B-lymphocyte origin, which are associated with the MYD88 gene with the L265P mutation; CXCR4 with oncogenic properties and changes in certain “signaling proteins” CD79B, MYD88 and others. They transmit an activating signal to cell proliferation genes through receptors on their surface, which are activated upon interaction with specific antigens, interleukins from macrophages, T-lymphocyte helpers, chemokines from bone marrow stromal cells, and lymph nodes. The mutual potentiating effect stimulates proliferation and uncontrolled activity of the tumor clone of lymphocytes. As a result of the analysis of the autopsy protocol and clinical and anatomical epicrisis of the case from the clinic, the course of Waldenström macroglobulinemia disease was clarified, and the possibilities of additional methods of verification of this pathology were explored.

Keywords:

B-lymphoplasmacytic lymphoma Waldenström macroglobulinemia pathomorphology

References:

1. Prokopiv MM, Polyukhovych OI, Kyselʹova OA , Illyash TI. Makrohlobulinemiya Valʹdenstrema: zahadka odnoho klinichnoho vypadku. Ukr Med J 2023;159. https://doi.org/10.32471/umj.1680-3051.159.249213. (Ukr)
2. Alcoceba M, García-Álvarez M, Medina A, Maldonado R, González-Calle V, Chillón MC, et al. MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. Int J Mol Sci 2022;23:5570. https://doi.org/10.3390/ijms23105570.
3. Bibas M, Castillo JJ, Sarosiek S. Waldenström Macroglobulinemia – A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems. Mediterr J Hematol Infect Dis 2024;16:e2023061. https://doi.org/10.4084/MJHID.2024.061.
4. Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, et al. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia. Leukemia 2023;37:388–95. https://doi.org/10.1038/s41375-022-01762-3.
5. Garcia-Sanz R, Varettoni M, Jiménez C, Ferrero S, Poulain S, San-Miguel JF, et al. Report of Consensus Panel 3 from the 11th International workshop on Waldenström’s Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström’s Macroglobulinemia. Semin Hematol 2023;60:90–6. https://doi.org/10.1053/j.seminhematol.2023.03.007.
6. Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol 2023;98:348–58. https://doi.org/10.1002/ajh.26796.
7. Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges. Leukemia 2021;35:333–45. https://doi.org/10.1038/s41375-020-01102-3.
8. McMaster ML. The epidemiology of Waldenström macroglobulinemia. Semin Hematol 2023;60:65–72. https://doi.org/10.1053/j.seminhematol.2023.03.008.
9. Pratt G, El‐Sharkawi D, Kothari J, D’Sa S, Auer R, McCarthy H, Krishna R, et al. Diagnosis and management of Waldenström macroglobulinaemia − A British Society for Haematology guideline. Br J Haematol 2022;197:171–87. https://doi.org/10.1111/bjh.18036.
10. Ravi G, Kapoor P. Current approach to Waldenström Macroglobulinemia. Cancer Treat Res Commun 2022;31:100527. https://doi.org/10.1016/j.ctarc.2022.100527.
11. Seon BK, Okazaki M, Duzen J, Matsuno F, Goey AKL, Maguire O. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b. Leuk Res 2024;136:107436. https://doi.org/10.1016/j.leukres.2024.107436.

Publication:

«World of Medicine and Biology» Vol. 21 No. 92 (2025) , с. 259-265
УДК 616-006.44:616.83-092

DOI:

https://doi.org/10.26724/2079-8334-2025-2-92-259-265